Series
Maze Therapeutics Secures $115 Million Series D Funding to Advance Clinical-Stage Kidney Disease Programs
Maze Therapeutics, Series D funding, kidney disease, clinical-stage programs, precision medicine, APOL1 kidney disease, chronic kidney disease, MZE829, MZE782.
Nabla Bio Revolutionizes AI-Driven Protein Design with $26M Series A Funding and Major Pharmaceutical Collaborations
Generative Protein Design, AI-Driven Drug Development, Therapeutic Antibodies, Multipass Membrane Proteins, Pharmaceutical Collaborations, Series A Funding
Arda Therapeutics Secures $43M Series A Funding to Pioneer ADCs for Fibrotic Diseases
Arda Therapeutics, Series A Funding, Fibrotic Diseases, Antibody-Drug Conjugates (ADCs), Eli Lilly, Andreessen Horowitz (a16z)
SpectraWAVE Secures $50M Series B Funding Led by J&J to Enhance Intravascular Imaging System
SpectraWAVE, Johnson & Johnson, intravascular imaging, HyperVue Imaging System, coronary artery disease, medical imaging, Series B funding
Superluminal Medicines Secures $120M Series A Funding to Advance Membrane Receptor Drugs into Clinical Trials
Superluminal Medicines, Series A funding, membrane receptor drugs, clinical trials, AI-focused biotech, Eli Lilly investment
Superluminal Secures $120M Series A Funding to Advance Membrane Receptor Drugs into Clinical Trials
Superluminal, Eli Lilly, Series A funding, membrane receptor drugs, clinical trials, biotech, pharmaceuticals
Navigator Medicines Launches with $100 Million Series A Funding to Advance Autoimmune Disease Bispecific Antibody
Navigator Medicines, autoimmune disease, bispecific antibody, Series A funding, RA Capital Management, Forbion
Pinetree Therapeutics Secures $17M in Funding to Advance Targeted Protein Degraders
Pinetree Therapeutics, targeted protein degraders, TPD, Series A funding, pharmaceutical development
VC Firm Oversees NGM Bio’s $122M Series A Funding After Taking it Private
NGM Bio, The Column Group, Venture Capital, Biotech, Series A Funding
SciRhom Secures €63 Million in Series A Funding for Autoimmune Therapies
SciRhom, autoimmune diseases, iRhom2, therapeutic strategy, Series A funding, biotech, pharmaceuticals